Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy

Cancer Letters

Volumn 280, Issue 1, 2009, Pages 15-30

  Sherbet, G V ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Cell proliferation; Invasion; Metastasis; S100A4; Therapeutic targets

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALVASCULIN; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CYTOSKELETON; GENE EXPRESSION; GENE SILENCING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SHORT SURVEY; TUMOR GROWTH;

EID: 67349171584     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.037     Document Type: Review

References (161)

1. Sherbet G.V. Calcium Signalling in Cancer (2001), CRC Press, Boca Raton, FL, USA
2. Marenholz I., Volz A., Ziegler A., Davies A., Ragoussis I., Korge B.P., et al. Genetic analysis of the epidermal differentiation complex (EDC) on human chromosome 1q21: chromosomal orientation, new markers, and a 6-Mb YAC contig. Genomics 37 (1996) 295-302
3. Mischke D., Korge B.P., Marenholz I., Volz A., and Ziegler A. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (''epidermal differentiation complex'') on human chromosome 1q21. J. Invest. Dermatol. 106 (1996) 989-992
4. Schafer B.W., Wicki R., Engelkamp D., Mattei M.G., and Heizmann C.W. Isolation of a yac clone covering a cluster sof 9 S100 genes on human chromsome 1Q21. Rationale for a new nomenclature of the S100 calcium binding protein family. Genomics 25 (1996) 638-643
5. Jackson-Grusby L., Swiergel J., and Linzer D. A growth related mRNA in cultured mouse cells encodes a placental calcium binding protein. Nucleic Acids Res. 15 (1987) 6677-6690
6. Masiakowski P., and Shooter E. Nerve growth factor induces genes for two proteins related to a family of calcium-binding proteins. Proc. Natl. Acad. Sci. USA 85 (1987) 1277-1281
7. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33 (2001) 637-668
8. Vallely K.M., Rustandi R.R., Ellis K.C., Varlamova O., Bresnick A.R., and Weber D.J. Solution structure of human Mts1 (S100A4) as determined by NMR spectroscopy. Biochemistry 41 (2002) 12670-12680
9. 2+-free S100A2 at 1.6-A resolution. J. Mol. Biol. 378 (2008) 931-940
10. Moroz O.V., Dodson G.G., Wilson K.S., Lukanidin E., and Bronstein I.B. Multiple structural states of S100A12: a key to its functional diversity. Microsc. Res. Tech. 60 (2003) 581-592
11. Zhang S., Wang G.Z., Liu D., Bao Z.Z., Fernig D.G., Rudland P.S., et al. The C-terminal region of S100A4 is important for its metastasis-inducing properties. Oncogene 24 (2005) 4401-4411
12. 2+-bound S100A4 and its interaction with peptides derived from nonmuscle myosin-IIA. Biochemistry 47 (2008) 111-5126
13. 2+-binding protein family. Biometals 11 (1998) 383-397
14. 2+-binding site on S100B as determined by NMR spectroscopy and site-directed mutagenesis. Biochemistry 42 (2003) 13410-13421
15. Wilder P.T., Varney K.M., Weiss M.B., Gitti R.K., and Weber D.J. Solution structure of zinc- and calcium-bound rat S100B as determined by nuclear magnetic resonance spectroscopy. Biochemistry 44 (2005) 5690-5702
16. Wang G.Z., Rudland P.S., White M.R., and Barraclough R. Interaction in vivo and in vitro of the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1. J. Biol. Chem. 275 (2000) 11141-11146
17. Kim E.J., and Helfman D.M. Characterization of the metastasis-associated protein, S100A4 - roles of calcium binding and dimerization in cellular localization and interaction with myosin. J. Biol. Chem. 278 (2003) 30063-30073
18. Garrett S.C., Hodgson L., Rybin A., Toutchkine A., Hahn K.M., et al. A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamics. Biochemistry 47 (2008) 986-996
19. Tarabykina S., Scott D.J., Herzyk P., Hill T.J., Tame J.R.H., Kriajevska M., et al. The dimerization interface of the metastasis-associated protein S100A4 (Mts1) - in vivo and in vitro studies. J. Biol. Chem. 276 (2001) 24212-24222
20. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med. 7 (2007) 711-724
21. Fernandez-Fernandez M.R., Veprintsev D.B., and Fersht A.R. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc. Natl. Acad. Sci. USA 102 (2005) 4735-4740
22. Pietsch E.C., Leu J.I.J., Frank A., Dumont P., George D.L., et al. The tetramerization domain of p53 is required for efficient BAK oligomerization. Cancer Biol. Ther. 6 (2007) 1576-1583
23. 2+-dependent interaction of S100B(beta beta) with a peptide derived from p53. Biochemistry 37 (1998) 1951-1960
24. Lin J., Blake M., Tang C., Zimmer D., Rustandi R.R., et al. Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J. Biol. Chem. 276 (2001) 35037-35041
25. Kulikov R., Winter M., and Blattner C. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J. Biol. Chem. 281 (2006) 28575-28583
26. Wilder P.T., Lin J., Bair C.L., Charpentier T.H., Yang D., et al. Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim. Biophys. Acta-Mol. Cell Res. 1763 (2006) 1284-1297
27. 2+-dependent interaction of S100B(beta beta) with a peptide derived from p53. Biochemistry 37 (1998) 1951-1960
28. Dulyaninova N.G., Malashkevich V.N., Almo S.C., and Bresnick A.R. Regulation of myosin-IIA assembly and Mts1 binding by heavy chain phosphorylation. Biochemistry 44 (2005) 6867-6876
29. Shi Y., Zou M., Collison K., Baitei E.Y., Al-Makhalafi Z., Farid N.R., et al. RNA interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of aplastic thyroid carcinoma in a mouse model. J. Clin. Endocrinol. Metab. 91 (2006) 2373-2379
30. Mackay A., Jones C., Dexter T., Silva R.L.A., Bulmer K., Jones A., et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22 (2003) 2680-2688
31. Parker C., Usmani B.A., Draper S., and Sherbet G.V. Metastasis associated genes MTS1, but not NM23, expression correlates with epidermal growth factor receptor status in human breast cancer tumour cell lines. J. Exp. Clin. Cancer Res. 11 (1992) 58
32. Sherbet G.V., Parker C., and Lakshmi M.S. Epidermal growth factor receptor status and cell proliferation and metastasis related 18A2/mts1 gene expression in human carcinoma cell lines. Proc. Am. Assoc. Cancer Res. 36 (1995) 168
33. Sherbet G.V., Parker C., Usmani B.A., and Lakshmi M.S. Epidermal growth factor receptor status correlates with cell proliferation related 18A2/mts1 gene expression in human carcinoma cell lines. Ann. NY Acad. Sci. 768 (1995) 272-276
34. Cajone F., Debiasi S., Parker C., Lakshmi M.S., and Sherbet G.V. Metastasis associated mts1 gene is down-regulated by heat shock in variant cell lines of the B16 murine melanoma. Melanoma Res. 4 (1994) 143-150
35. Parker C., Lakshmi M.S., Piura B., and Sherbet G.V. Metastasis associated mts1 gene expression correlates with increased p53 expression. DNA Cell Biol. 13 (1994) 343-351
36. Parker C., Whittaker P.A., Usmani B.A., Lakshmi M.S., and Sherbet G.V. Induction of 18A2/mts1 gene expression and its effects on metastasis and cell cycle control. DNA Cell Biol. 13 (1994) 1021-1028
37. Sherbet G.V., and Lakshmi M.S. The modus operandi of S100A4 signalling in cancer growth, progression and prognosis. In: Sherbet G.V. (Ed). Molecular and Cellular Pathology of Cancer Progression and Prognosis (2006), Transworld Research Network, Trivandrum pp. 359-377
38. Grigorian M., and Lukanidin E. Metastasis-inducing Mts1/S100A4 protein binds to tumour suppressor p53 protein. Russ. J. Genet. 39 (2003) 748-755
39. Grigorian M., Andresen S., Tulchinsky E., Kriajevska M., Carlberg C., Kruse C., et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein - functional consequences of their interaction. J. Biol. Chem. 276 (2001) 22699-22708
40. Cajone F., and Sherbet G.V. Stathmin is involved in S100A4-mediated regulation of cell cycle progression. Clin. Exp. Metastasis 17 (1999) 865-871
41. Chen H.L., Fernig D.G., Rudland P.S., Sparks A., Wilkinson M.C., and BarracloughR R. Binding to intracellular targets of the metastasis-inducing protein, S100A (p9Ka). Biochem. Biophys. Res. Commun. 266 (2001) 1212-1217
42. Schmidt-Hansen B., Klingelhofer J., Grum-Schwensen B., Christensen A., Andresen S., Kruse C., et al. Functional significance of metastasis-inducing S100A4 (Mts1) in tumour-stroma interplay. J. Biol. Chem. 279 (2004) 24498-24504
43. 2+-binding modulator protein involved in cell proliferation and in cell death. Biochim. Biophys. Acta Proteins Proteomics 1600 (2002) 68-73
44. El Naaman C., Grum-Schwensen B., Mansouri A., Grigorian M., Santoni-Rugiu E., Hansen T., et al. Cancer predisposition in mice deficient for the metastasis-associated Mts1 (S100A4) gene. Oncogene 23 (2004) 3670-3680
45. Basile A., Biziato D., Sherbet G.V., Comi P., and Cajone F. Hyperthermia inhibits cell proliferation and induces apoptosis: relative signaling status of p53, S100A4, and notch in heat sensitive and resistant cell lines. J. Cell. Biochem. 103 (2008) 212-220
46. Mahon P.C., Baril P., Bhakta V., Chelala C., Caulee K., Harada T., et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 67 (2007) 6786-6795
47. Matsumoto T., Murao S., Kito K., Kihana T., Matsuura S., and Ueda N. Modulation of S-100 genes response to growth conditions in human epithelial tumor cells. Pathol. Int. 47 (1997) 339-346
48. Fields A.L., Soprano D.R., and Soprano K.J. Retinoids in biological control and cancer. J. Cell. Biochem. 102 (2007) 886-898
49. Lakard S., Lesniewska E., Michel G., Lakard B., Morrand-Villeneuve N., and Versaux-Botteri C. In vitro induction of differentiation by retinoic acid in an immortalized olfactory neuronal cell line. Acta Histochem. 109 (2007) 111-121
50. Sherbet G.V., and Lakshmi M.S. Retinoid and growth factor signal transduction. In: Sherbet G.V. (Ed). Retinoids: Their Physiological Function and Therapeutic Potential (1997), JAI Press, Inc., Greenwich, Conn. and London pp. 141-159
51. Karmakar S., Banik N.L., Patel S.J., and Ray S.K. Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis 12 (2007) 2077-2087
52. Sherbet G.V., and Jackson S. Temperature-dependent surface charge modulation membrane fluidity and metastatic ability of L5178Y lymphoma. Anticancer Res. 6 (1986) 129-134
53. Sherbet G.V. Membrane fluidity and cancer metastasis. Exp. Cell Biol. 57 (1989) 198-205
54. Radotra B., McCormick D., and Crockard A. CD44 plays a role in adhesive interactions between glioma cells and extracellular matrix components. Neuropathol. Appl. Neurobiol. 20 (1994)
55. Merzak A., Koochekpour S., and Pilkington C.J. CD44 mediates glioma cell adhesion and invasion in vitro. Cancer Res. 54 (1994) 3988-3992
56. Lakshmi M.S., Parker C., and Sherbet G.V. Expression of the transmembrane glycoprotein CD44 and metastasis associated 18A2/mts1 gene in B16 murine melanoma cells. Anticancer Res. 17 (1997) 3451-3456
57. 2+ and the calmodulin inhibitor W-7 alter the expression of metastasis associated genes Mts1 and nm23 in metastatic variants of the B16 murine melanoma. Melanoma Res. 2 (1992) 337-343
58. Lakshmi M.S., Parker C., and Sherbet G.V. Metastasis-associated Mts1 and nm23 genes affect tubulin polymerisation in B16 melanomas. A possible mechanism of their regulation of metastatic behaviour of tumours. Anticancer Res. 13 (1993) 299-303
59. Parker C., Piura B., and Sherbet G.V. Taxol, a promoter of microtubule polymerisation, down regulates metastasis associated mts1 gene in the B16 murine melanoma. Proc. Am. Assoc. Cancer Res. 34 (1993) 62
60. Belot N., Pochet R., Heizmann C.W., Kiss R., and Decaestecker C. Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim. Biophys. Acta Proteins Proteomics 1600 (2002) 74-83
61. Li Z.H., Spektor A., Varlamova O., and Bresnick A.R. Mts1 regulates the assembly of nonmuscle myosin-IIA. Biochemistry 42 (2003) 4258-14266
62. Li Z.H., and Bresnick A.R. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res. 66 (2006) 5173-5180
63. Matsubara D., Nik T., Ishikawa S., Goto A., Ohara E., Yokomizo T., et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci. 96 (2005) 844-857
64. Matsumoto K., Irie A., Satoh T., Ishii J., Iwabuchi K., Iwamura M., et al. Expression of S10OA2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology 70 (2007) 602-607
65. Perl A.K., Wilgenbus P., Dahl U., Semb H., and Christofori G.A. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 382 (1998) 190-193
66. Vleminckx K., Vakaet L., Mareel M., Fiers W., and Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66 (1989) 107-119
67. Saunders R.M., Holt M.R., Jennings L., Sutton D.H., Barsukov I.L., et al. Role of vinculin in regulating focal adhesion turnover. Eur. J. Cell Biol. 85 (2006) 487-500
68. Ziegler W.H., Gingras A.R., Critchley D.R., and Emsley J. Integrin connections to the cytoskeleton through talin and vinculin. Biochem. Soc. Trans. 36 (2008) 235-239
69. Sherbet G.V., and Lakshmi M.S. The Genetics of Cancer: Genes associated with Cancer Invasion, Metastasis and Cell Proliferation (1997), Academic Press, London
70. Mejlvang J., Kriajeuska M., Berditchevski F., Bronstein L., Lukanidin E.M., Pringle J.H., et al. Characterization of E-cadherin-dependent and independent events in a new model of c-Fos-mediated epithelial mesenchymal transition. Exp. Cell Res. 313 (2007) 380-393
71. Yonemura Y., Ninomiya I., Kaji M., Sugiyama K., Fujimura T., Tsuchihara K., et al. Decreased E-cadherin expression correlates with poor survival in patients with gastric cancer. Anal. Cell. Pathol. 8 (1995) 177-190
72. Yonemura Y., Endou Y., Kimura K., Fushida S., Bandou E., Taniguch K., et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin. Cancer Res. 6 (2000) 4234-4242
73. Ikoma N., Yamazaki H., Abe Y., Oida Y., Ohnishi Y., Suemizu H., et al. S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gamma(null)(C) (NOG) mouse model. Oncol. Rep. 14 (2005) 633-637
74. Moriyama-Kita M., Endo Y., Yonemura Y., Heizmann C.W., Miyamori H., Sato H., et al. S100A4 regulates E-cadherin expression in oral squamous cell carcinoma. Cancer Lett. 230 (2005) 211-218
75. Andersen K., Nesland J.M., Holm R., Florenes V.A., Fodstad O., and Maelandsmo G.M. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod. Pathol. 17 (2004) 990-997
76. Miyazaki N., Abe Y., Oida Y., Suemizu H., Nishi M., Yamazaki H., et al. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression. Int. J. Oncol. 28 (2006) 1369-1374
77. Oida Y., Yamazaki H., Tobita K., Mukai M., Ohtani Y., Miyazaki N., et al. Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol. Rep. 16 (2006) 457-463
78. Ambartsumian N., Klingelhofer J., Grigorian M., Christensen C., Kriajevska M., Tulchinsky E., et al. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 20 (2001) 4685-4695
79. de Silva-Rudland S., Martin L., Roshanlall C., Winstanley J., Leinster S., Platt-Higgins A., et al. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin. Cancer Res. 12 (2006) 1192-1200
80. Timar J., and Dome B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med. Chem. 8 (2008) 462-469
81. Handsley M.M., and Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115 (2005) 849-860
82. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9 (2005) 267-285
83. S.C. Bellum, C Mouta, Molecular mechanisms of cancer metastasis, in: G.V. Sherbet (Ed.), Molecular and Cellular Pathology of Cancer Progression and Prognosis, Transworld Research Network, Trivandrum, 2006. pp. 53-72, ISBN 81-7736-283-6.
84. P. Gaßmann, J. Haier, Molecular mechanisms of cancer metastasis, in: G.V. Sherbet (Ed.), Molecular and Cellular Pathology of Cancer Progression and Prognosis, Transworld Research Network, Trivandrum, 2006. pp. 1-52, ISBN 81-7736-283-6.
85. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161 (2003) 1163-1177
86. Merzak A., Parker C., Koochekpour S., Sherbet G.V., and Pilkington J.G. Over-expression of the 18A2/mts1 gene and down regulation of the TIMP-2 gene in invasive human glioma cell lines. Neuropath. Appl. Neurobiol. 6 (1994) 143-150
87. Bjornland K., Winberg J.O., Odegaard O.T., Hovig E., and Loennechen T. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 59 (1999) 4702-4708
88. Mathisen B., Lindstad R.I., Hansen J., El-Gewely S.A., Maelandsmo G.M., et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin. Exp. Metastasis 20 8 (2003) 701-711
89. Gao X.N., Tang S.Q., and Zhang X.F. S100A4 antisense oligodeoxynucteotide suppresses invasive potential of neuroblastoma cells. J. Pediat. Surg. 40 (2005) 648-652
90. Saleem M., Kweon M.H., Johnson J.J., Adhami V.M., Elcheva I., et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc. Natl. Acad. Sci. USA 103 (2006) 14825-14830
91. Yammani R.R., Carlson C.S., Bresnick A.R., and Loeser R.F. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum. 24 (2006) 2901-2911
92. Samolov B., Steen B., Seregard S., van der Ploeg I., Montan P., and Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp. Eye Res. 80 (2005) 159-166
93. Schmidt-Hansen B., Klingelhofer J., Grum-Schwensen B., Christensen A., Andresen S., Kruse C., et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumour-stroma interplay. J. Biol. Chem. 279 (2004) 24498-24504
94. Greenway S., van Suylen R.J., Sarvaas G.D., Kwan E., Ambartsumian N., Lukanidin E., et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am. J. Pathol. 164 (2004) 253-262
95. Spurgeon K.R., Donohoe D.L., and Basile D.P. Transforming growth factor-beta in acute renal failure: receptor expression, effects on proliferation, cellularity, and vascularization after recovery from injury. Am. J. Physiol. Renal Physiol. 288 (2005) F568-F577
96. Asami Y., Kakeya H., Onose R., Chang Y.H., Toi M., and Osada H. RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine. Tetrahedron 60 (2004) 7085-7091
97. Bernier S.G., Douglas D., Lazarus D.D., Clark E., Doylem B., Labensk M.T., et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 101 (2004) 10768-10773
98. Endo H., Takenaga K., Kanno T., Satoh H., and Mori S. Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S10OA4. J. Biol. Chem. 77 (2002) 26396-26402
99. Brabletz T., Jung A., Dag S., Hlubek F., and Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155 (1999) 1033-1038
100. Sen M., Reifert J., Lauterbach K., Wolf V., Rubin J.S., Corr M., et al. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum. 46 (2002) 2867-2877
101. Lowy A.M., Clements W.M., Bishop J., Kong L., Bonney T., Sisco K., et al. Beta-catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. Cancer Res. 66 (2006) 4734-4741
102. Han J.C., Zhang K.L., Chen X.Y., Jiang H.F., Sun Q.Y.K.;Y., et al. Expression of seven gastric cancer-associated genes and its relevance for Wnt, NF-kappa B and Stat3 signaling. APMIS 115 (2007) 1331-1343
103. Masckauchan T.N.H., Agalliu D., Vorontchikhina M., Ahn A., Parmalee N.L., Li C.M., et al. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol. Biol. Cell 17 (2006) 5163-5172
104. Marchenko N.D., Marchenko G.N., Weinreb R.N., Lindsey J.D., Kyshtoobayeva A., Crawford H.C., et al. Beta-catenin regulates the gene of MMP-26, a novel matrix metalloproteinase expressed both in carcinomas and normal epithelial cells. Int. J. Biochem. Cell Biol. 36 (2004) 942-956
105. Wu B.B., Crampton S.P., and Hughes C.C.W. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26 (2007) 227-239
106. Lyu J., and Joo C.K. Wnt-7a up-regulates matrix metalloproteinase-12 expression and promotes cell proliferation in corneal epithelial cells during wound healing. J. Biol. Chem. 280 (2005) 21653-21660
107. Cowden Dahl K.D., Symowicz J., Ning Y., Gutierrez E., Fishman D.A., et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res. 68 (2008) 4606-4613
108. Asano T., Tada M., Cheng S., Takemoto N., Kuramae T., et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J. Surg. Res. 146 (2008) 32-42
109. Langers A.M.J., Sier C.F.M., Hawinkels L.J.A.C., Kubben F.J.G.M., and van Duijn W. MMP-2 geno-phenotype is prognostic for colorectal cancer survival whereas MMP-9 is not. Br. J. Cancer 98 (2008) 1820-1823
110. Tian X., Cong M., Zhou W., Zhu J., and Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J. Int. Med. Res. 36 (2008) 699-703
111. Chiang Y.Y., Tsai M.H., Lin T.Y., and Chiang I.P. Expression profile of metastasis-related genes in invasive oral cancers. Histol. Histopathol. 23 (2008) 1213-1222
112. Pettaway C.A., Song R., Wang X., Sanchez-Ortiz R., Spiess P.E., et al. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate 68 (2008) 1467-1476
113. M McGowan P., and Duffy M.J. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann. Oncol. 19 (2008) 1566-1572
114. Giannopoulos G., Pavlakis K., Parasi A., Kavatzas N., Tiniakos D., et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 28 (2008) 1875-1881
115. Sauter W., Rosenberger A., Beckmann L., Kropp S., Mittelstrass K., et al. Cancer Epidemidol. Biomarkers Prevent. 17 (2008) 1127-1135
116. Fingleton B. MMPs as therapeutic targets - still a viable option?. Semin. Cell Develop. Biol. 19 (2008) 61-68
117. Klingelhofer J., Ambartsumian N.S., and Lukanidin E.M. Expression of the metastasis-associated mts1 gene during mouse development. Dev. Dyn. 210 (1997) 87-95
118. Stary M., Schneider M., Sheikh S.P., and Weitzer G. Parietal endoderm secreted S100A4 promotes early cardiomyogenesis in embryoid bodies. Biochem. Biophys. Res. Commun. 343 (2006) 555-563
119. Kato C., Kojima T., Komaki M., Mimori K., Duarte W.R., Takenaga E., et al. S100A4 inhibition by RNAi up-regulates osteoblast related genes in periodontal ligament cells. Biochem. Biophys. Res. Commun. 326 (2005) 147-153
120. Duarte W.R., Shibata T., Takenaga K., Takahashi E., Kubota K., Ohya K., et al. S100A4: a novel negative regulator of mineralization and osteoblast differentiation. J. Bone Miner. Res. 16 (2003) 493-501
121. Harland R., and Gerhart J. Formation and function of Spemann's organizer. Annu. Rev. Cell Dev. Biol. 13 (1997) 611-667
122. Wodarz A., and Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14 (1998) 59-88
123. Logan C.Y., and Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20 (2004) 781-810
124. Kohn A.D., and Moon R.T. Wnt and calcium signaling: beta-catenin-independent pathways. Cell. Calcium 38 (2005) 439-446
125. Kestler H.A., and Kuhl M. From individual Wnt pathways towards a Wnt signalling network. Phil. Trans. Royal Soc. B Biol. Sci. 363 (2008) 1333-1347
126. Whitaker M., and Smith J. Introduction: calcium signals and developmental patterning. Phil. Trans. Royal Soc. B Biol. Sci. 363 (2008) 1307-1310
127. 2+ signaling in neurons induced by the S100A4 protein. Mol. Cell. Biol. 26 (2006) 3625-3638
128. Wang L.Y., Li S.T., and Jungalwala F.B. Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J. Neurosci. Res. 86 (2008) 1254-1266
129. Stein U., Arlt F., Walther W., Smith J., Waldman T., Harris E.D., et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenerology 131 (2006) 1486-1500
130. Hlubek F., Brabletz T., Budczies J., Pfeiffer S., Jung A., and Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int. J. Cancer 121 (2007) 1941-1948
131. Hudson B.I., Carter A.M., Harja E., Kalea A.Z., Arriero M., Yang H., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22 (2008) 1572-1580
132. Logsdon C.D., Fuentes M.K., Huang E.H., and Arumugam T. RAGE and RAGE ligands in cancer. Curr. Mol. Med. 7 (2007) 777-789
133. Grigorian L.S.;M., Lukanidin E., Simmen B., Michel B.A., Pavelka K., et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Ann. Rheum. Dis. 65 (2006) 1645-1648
134. Galichet A., Weibel M., and Heizmann C.W. Calcium-regulated intra-membrane proteolysis of the RAGE receptor. Biochem. Biophys. Res. Commun. 370 (2008) 1-5
135. Maelandsmo G.M., Hovig E., Skrede M., Engebraaten O., Florenes V., et al. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res. 56 (1996) 5490-5498
136. Steeg P.S., Ouatas T., Halverson D., Palmieri D., and Salerno M. ] Metastasis suppressor genes: basic biology and potential clinical use. Clin. Breast Cancer 4 (2003) 1-62
137. Palmieri D., Horak C.E., Lee J.H., Halverson D.O., and Steeg P.S. Translational approaches using metastasis suppressor genes. J. Bioienerget. Biomemb. 38 (2006) 151-161
138. Palmieri D., Halverson D.O., Ouatas T., Horak C.E., Salerno M., et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 97 (2005) 632-642
139. Tanaka Y., Kato K., Mibu R., Uchida S., Asanoma K., et al. Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression. Menopause-J. North Am., Menopause Soc. 15 (2008) 442-453
140. Altinoz M.A., Bilir A., Gedikoglu G., Ozcan E., Oktem G., et al. Medroxyprogesterone and tamoxifen augment anti-proliferative efficacy and reduce mitochondria-toxicity of epirubicin in FM3A tumor cells in vitro. Cell Biol. Int. 31 (2007) 473-481
141. Sherbet G.V. Genetic Recombination in Cancer (2003), Academic/Elsevier Press, London
142. Nakao M. Epigenetics: interaction of DNA methylation and chromatin. Gene 278 (2001) 25-31
143. Vercelli D. Genetics, epigenetics, and the environment: switching, buffering, releasing. J. Allergy Clin. Immunol. 113 (2004) 381-386
144. Nakamura N., and Takenaga K. Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin. Exp. Metastasis 16 (1998) 471-479
145. Sato N., Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 63 (2003) 4158-4166
146. Rosty C., Ueki T., Argani P., Jansen M., and Yeo C.J. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160 (2002) 45-50
147. Xie R., Loose D.S., Shipley G.L., Xie S.S., Bassett R.L., and Broaddus R.R. Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod. Pathol. 20 (2007) 1045-1054
148. Lindsey J.C., Lusher M.E., Anderton J.A., Gilbertson R.J., Ellison D.W., and Clifford S.C. Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br. J. Cancer 97 (2007) 267-274
149. Stresemann C., and Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123 (2008) 8-13
150. Hamilton A., and Baulcombe D. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286 (1999) 950-952
151. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
152. Elbashir S., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
153. Jones L., Hamilton A.J., Voinnet O., Thomas C.L., Maule A.J., and Baulcombe D.C. RNA-DNA interactions and DNA methylation in post-transcriptional gene silencing. Plant Cell 11 (1999) 2291-2301
154. Suzuki K., Juelich T., Lim H., Ishida T., Watanebe T., et al. Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J. Biol. Chem. 283 (2008) 23353-23363
155. Li L.C., Okino S.T., Zhao H., Pookot D., Place R.F., et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 103 (2006) 7337-17342
156. Kidokoro T., Tankikwa C., Furukawa Y., Katagiri T., Nakamura Y., et al. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27 (2008) 1562-1571
157. Lin M., Chang J.K., Shankar D., and Sakamoto K.M. The role of p55CDC in cell cycle control and mammalian cell proliferation, differentiation, and apoptosis. Exp. Mol. Pathol. 74 (2003) 123-128
158. Makino K., Yu D.H., and Hung M.C. Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis. Oncogene 20 (2001) 2537-2543
159. Lin M.L., and Sakamoto K.M. P55Cdc/Cdc20 overexpression promotes early G(1)/S transition in myeloid cells. Stem Cells 19 (2001) 205-211
160. Sherbet G.V., and Cajone F. Stathmin in cell proliferation and cancer progression. Cancer Genomics Proteomics 2 (2005) 227-238
161. Albertazzi E., Cajone F., Leone B.E., Naguib R.N.G., Lakshmi M.S., and Sherbet G.V. The expression of metastasis associated genes mts1 and nm23 in carcinoma of the breast are related to disease progression. DNA Cell Biol. 17 (1998) 335-342